soon have their own specially formulated injectable GLP-1 for them! US biotechnology company OKAVA announced the success of its first clinical trial of a GLP-1 booster for cats, "MEOW-1".
According to OKAVA's press release, this pet-specific GLP-1 has the potential to improve pets' quality of life, promote healthy aging, and even become the "most influential lifespan extension therapy" for felines. In addition to simple weight loss, it can also address common feline metabolic diseases such as diabetes and kidney disease, contributing to healthy aging and extended lifespan.
OKAVA CEO Michael Klotsman stated that calorie restriction or fasting for cats is one of the most mature interventions for extending feline lifespan and improving their metabolic health, but it is also the most difficult to maintain.
Klotsman explained that implanting the long-acting device OKV-119 subcutaneously in cats can allow the drug to be slowly released into the cat's body over a period of up to six months. This design aims to improve insulin sensitivity, reduce fat mass, and metabolize energy more efficiently without requiring changes to feeding or disrupting the food-based bond between owner and pet.
The successful Phase 1 clinical trial brings hope to owners struggling to help their overweight cats lose weight. If the "MEOW-1" trial is ultimately successful, OKAVA plans to launch a larger-scale trial and apply for approval from the U.S. Food and Drug Administration (FDA), hoping that OKV-119 could be available as early as 2028 or 2029.
0 Comments:
Post a Comment